RxDoctor Payments Data

Barrett Newsome, DO

Hematology & Oncology · Northampton, MANPI 1932293479

Payments from drug & device makers

$21,843in general payments, 2019–2025

Across 42 payments — averaging $520.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$5K
  • AstraZeneca$5K
  • Avyxa Pharma, LLC$4K
  • Sanofi$3K
  • Exelixis Inc.$3K
  • BD$920
  • plus $2K from 4 others

What the payments were for

  • Consulting fees$13,73263%
  • Speaking & faculty fees$3,96018%
  • Travel & lodging$3,07214%
  • Food & beverage$1,0495%
  • Education$310%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation11$5,144
AstraZeneca8$4,698
Avyxa Pharma, LLC6$3,888
Sanofi4$2,907
Exelixis Inc.6$2,730
BD2$920
Beigene USA, Inc.1$675
Daiichi Sankyo Inc.1$650
Sobi, Inc1$200
Pfizer2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,843 in reported general payments places this provider in the 50th percentile of 374 hematology & oncology providers in Massachusetts.

See all hematology & oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$195,617
Medicare patients
452
Services billed
2,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide71$898,360
VenclextaVenetoclax56$667,363
RevlimidLenalidomide40$639,233
Lenalidomide46$581,289
TagrissoOsimertinib Mesylate35$574,417
PomalystPomalidomide21$466,308
LenvimaLenvatinib Mesylate15$347,015
JakafiRuxolitinib Phosphate18$307,149
SprycelDasatinib33$274,788
Everolimus21$186,395
MekinistTrametinib Dimethyl Sulfoxide13$180,804
TafinlarDabrafenib Mesylate14$179,412
ErleadaApalutamide12$172,606
BrukinsaZanubrutinib14$120,291
Abiraterone Acetate60$29,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$4,698$574,41735 claims
Incyte CorporationJakafi$5,144$307,14918 claims
Beigene USA, Inc.Brukinsa$675$120,29114 claims
PfizerEliquis$31$11,19311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 374 hematology & oncology providers in Massachusetts.

Other hematology & oncology in Northampton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →